MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com

A Hepatic Impairment Study for PF-04965842.

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
First Posted Date
2018-08-13
Last Posted Date
2020-05-18
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT03626415
Locations
🇺🇸

Prism Clinical Research, LLC, Saint Paul, Minnesota, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Glasdegib

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
First Posted Date
2018-08-13
Last Posted Date
2019-05-06
Lead Sponsor
Pfizer
Target Recruit Count
24
Registration Number
NCT03627754
Locations
🇺🇸

Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Research Pharmacy, Miami, Florida, United States

🇺🇸

University of Miami Division of Clinical Pharmacology, Miami, Florida, United States

🇺🇸

Orlando Clinical Research Center, Orlando, Florida, United States

Bioequivalence (BE) Study Comparing Fluconazole 150mg Capsule Manufactured in China and in France

First Posted Date
2018-08-08
Last Posted Date
2021-07-16
Lead Sponsor
Pfizer
Target Recruit Count
36
Registration Number
NCT03621072
Locations
🇨🇳

Wuxi People's Hospital//Phase One Unit, Wuxi, Jiangsu, China

A Study of Benzathine Benzylpenicillin Intramuscular Injection in Japanese Healthy Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2018-08-02
Last Posted Date
2018-10-10
Lead Sponsor
Pfizer
Target Recruit Count
8
Registration Number
NCT03612557
Locations
🇯🇵

P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan

A STUDY TO ESTIMATE THE EFFECT OF PF-06651600 ON THE PHARMACOKINETICS (PK) OF ORAL CONTRACEPTIVE (OC)

Phase 1
Completed
Conditions
Healthy Females
Interventions
First Posted Date
2018-07-31
Last Posted Date
2019-04-09
Lead Sponsor
Pfizer
Target Recruit Count
12
Registration Number
NCT03608241
Locations
🇺🇸

Quotient Sciences-Miami, Inc., Miami, Florida, United States

🇺🇸

Quotient Sciences, Coral Gables, Florida, United States

Singe Dose, First in Human Study of PF- 06946860 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Biological: PF-06946860
Other: Placebo
First Posted Date
2018-07-26
Last Posted Date
2019-11-08
Lead Sponsor
Pfizer
Target Recruit Count
63
Registration Number
NCT03599063
Locations
🇺🇸

Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Glasdegib Renal Impairment Study

First Posted Date
2018-07-24
Last Posted Date
2019-08-29
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT03596567
Locations
🇺🇸

Prism Clinical Research LLC, Saint Paul, Minnesota, United States

🇺🇸

University of Miami Division of Clinical Pharmacology, Miami, Florida, United States

🇺🇸

University of Miami, Sylvester Comprehensive Cancer Center, Miami, Florida, United States

A Single and Multiple Dose Study of PF-05221304 in Healthy Japanese Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2018-07-24
Last Posted Date
2018-11-27
Lead Sponsor
Pfizer
Target Recruit Count
15
Registration Number
NCT03597217
Locations
🇯🇵

P-one Clinic, Keikokai Medical Corporation, Hachioji-shi, Tokyo, Japan

Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2018-07-20
Last Posted Date
2019-03-28
Lead Sponsor
Pfizer
Target Recruit Count
18
Registration Number
NCT03593707
Locations
🇧🇪

Pfizer Clinical Research Unit, Brussels, Belgium

A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

Phase 3
Completed
Conditions
Hemophilia B
Hemophilia A
Interventions
Drug: Standard of Care FIX Replacement therapy
Drug: Standard of Care FVIII Replacement therapy
First Posted Date
2018-07-16
Last Posted Date
2025-04-24
Lead Sponsor
Pfizer
Target Recruit Count
213
Registration Number
NCT03587116
Locations
🇮🇹

UOC Medicina Interna - Malattie Emorragiche e Trombotiche, Napoli, Naples, Italy

🇺🇸

Stanford Health Care, Stanford, California, United States

🇧🇪

Cliniques universitaires Saint-Luc/Unité d'Hématology et Hémostase, Brussels, Belgium

and more 72 locations
© Copyright 2025. All Rights Reserved by MedPath